ArticleJournal of oncology2022
Machine Learning-Based Integration Develops a Pyroptosis-Related lncRNA Model to Enhance the Predicted Value of Low-Grade Glioma Patients.
Article in Journal of oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Pyroptosis as a novel therapeutic target in glioblastoma multiforme: Mechanisms, molecular insights, and therapeutic potential.Molecular therapy. Nucleic acids · 2026Review
- Roles of Pyroptosis-Related Genes in the Diagnosis and Subtype Classification of Periodontitis.Journal of immunology research · 2023Article
- Identification of pyroptosis-related subtypes, development of a prognostic model, and characterization of tumour microenvironment infiltration in gastric cancer.Frontiers in genetics · 2022Article
- Identification of pyroptosis-related lncRNA signature and AC005253.1 as a pyroptosis-related oncogene in prostate cancer.Frontiers in oncology · 2022Article
- Prognostic implications of necroptosis-related long noncoding RNA signatures in muscle-invasive bladder cancer.Frontiers in genetics · 2022Article
- An immunogenic cell death-related regulators classification patterns and immune microenvironment infiltration characterization in intracranial aneurysm based on machine learning.Frontiers in immunology · 2022Article
- Intelligent Nanoparticles With pH-Sensitive Co-Delivery of Temozolomide and siEGFR to Ameliorate Glioma Therapy.Frontiers in genetics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Molecular features have been included in the categorization of gliomas because they may be excellent predictors of tumor prognosis. Lower-grade glioma (LGGs, which comprise grade 2 and grade 3 gliomas) patients have a wide variety of outcomes. The goal of this research is to investigate a pyroptosis-based long noncoding RNA (lncRNA) profile and see whether it can be used to predict LGG prognosis. Methods: The Genotype-Tissue Expression (GTEx) and Cancer Genome Atlas (TCGA) datasets were utilized to get RNA data and clinical information for this research. Six considerably related lncRNAs (AL355574.1, AL355974.2, Z97989.1, SNAI3-AS1, LINC02593, and CYTOR) were selected using Cox regression (univariate and multivariate) and LASSO Cox regression. A variety of statistical techniques, including ROC curves, nomogram, and Kaplan-Meier curves, were utilized to verify the risk score's accuracy. Following that, bioinformatics studies were carried out to investigate the possible molecular processes that influence LGG prognosis. The variations in pathway enrichment were investigated using GSEA. The immune microenvironment inconsistencies were investigated using CIBERSORT, ESTIMATE, MCPcounter, TIMER algorithms, and ssGSEA. Results: We discovered six lncRNAs with distinct expression patterns that are linked to LGG prognosis. Kaplan-Meier studies showed a signature of high-risk lncRNAs associated with a poor prognosis for LGG. Furthermore, the AUC of the lncRNA signature was 0.763, indicating that they may be used to predict LGG prognosis. In predicting LGG prognosis, our risk assessment approach outperformed conventional clinicopathological characteristics. In the high-risk group of people, GSEA identified tumor-related pathways and immune-related pathways. Furthermore, T cell-related activities such as T cell coinhibition and costimulation, check point, APC coinhibition and costimulation, CCR, and inflammatory promoting were shown to be substantially different between the two groups in TCGA analysis. Immune checkpoints including PD-1, CTLA4, and PD-L1 were expressed differentially in the two groups as well. Conclusion: This study found that pyroptosis-based lncRNAs were useful in predicting LGG patients' survival, suggesting that they may be used as a therapeutic target in the future.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.